• Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Careers
  • Tools
Finnegan
    • AIA Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • IP FDA Blog
    • Prosecution First Blog
  • Articles
  • IP Updates
  • Podcasts
  • Events
  • Webinars
  • Books

AIA Blog

IPR and CBM Statistics for Final Written Decisions Issued in June 2020

October 9, 2020

By Daniel F. Klodowski; Michael R. Galgano; Zachery D. Olah

Edited by Aaron L. Parker; Elliot C. Cook

The Patent Trial and Appeal Board issued 28 IPR and CBM Final Written Decisions in June, including decisions following remands from the Federal Circuit, cancelling 234 (72.67%) instituted claims while declining to cancel 88 (27.33%) instituted claims.  Patent owners did not concede any instituted claims through motions to amend or disclaimer in cases reaching a final decision.  For comparison, the cumulative average rate of instituted claims cancelled in IPR and CBM Final Written Decisions is about 74%.

On a per-case basis, no instituted or substitute claims survived in 15 (53.57%) decisions, all instituted claims survived in 7 (25%) decisions, and a mixed outcome occurred in 6 (21.43%) decisions.  A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision. 

The overall cumulative instituted claim survival rate, broken down by technology center, is as follows:

More detailed cumulative statistics on the Board’s IPR and CBM decisions, updated through June 30, 2020, are available here on the AIA Blog. 

Statistics regarding the outcome of appeals to the Federal Circuit are available here.

Numbers of final written decisions by technology center and instituted claim survival rates by technology center are available here. 

Various other PTAB metrics collected and generated by Finnegan are reserved for the use of Finnegan and its clients.  Stay tuned to the AIA Blog for the latest updates, analysis, and statistics on all aspects of PTAB and Federal Circuit practice.  Subscribe to the AIA Blog at the bottom of the page to receive notifications of new posts via email.

Tags

Patent Trial and Appeal Board (PTAB), Final Written Decision, AIA statistics

Related Practices

Patent Litigation

Appeals

Post-Grant Proceedings

IPR, PGR, and CBM

Contacts

Daniel_Klodowski
Daniel F. Klodowski
Associate
Washington, D.C.
+1 202 408 4216
Email
Michael_Galgano
Michael R. Galgano
Associate
Washington, D.C.
+1 202 408 4153
Email
Zachery D. Olah
Associate
Washington, D.C.
+1 202 408 4390
Email
Aaron_Parker
Aaron L. Parker
Partner
Washington, D.C.
+1 202 408 4387
Email
Elliot_Cook
Elliot C. Cook
Partner
Reston, VA
+1 571 203 2738
Email

Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

Best Practices in Intellectual Property 2021

June 14-15, 2021

Tel Aviv

Webinar

Patent Law Institute 2021: Critical Issues & Best Practices

April 29-30, 2021

Webinar

Webinar

Patent Law Institute 2021: Critical Issues & Best Practices

April 1-2, 2021

Webinar

Seminar

FORUM!Live: Patent Claim Construction

March 24-25, 2021

Virtual

Webinar

Patent Claim and Specification Drafting and Prosecution

March 11, 2021

Webinar

Webinar

Patent Year in Review: Key Decisions, Trends, and Strategies

February 25, 2021

Webinar

Conference

Pharma & Biotech Patent Litigation in Europe

February 23-25, 2021

Virtual

Webinar

Patenting Pharmaceutical Drug Formulations: Withstanding Litigation and PTAB Challenges

February 16, 2021

Webinar

Conference

2021 AIPLA Virtual Mid-Winter Institute

February 1-5, 2021

Virtual

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

  • Privacy
  • Disclaimer
  • EEO Statement

© 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP